Dyne at ‘attractive entry point’ following pullback, says Chardan

Why did US jobless claims drop last week? How will Iran-Israel tensions affect global oil prices? What impact will Nippon Steel’s US Steel takeover have? Why is Amazon cutting corporate jobs with AI? How does Senate’s stablecoin bill affect crypto markets? Why is the US housing market slump worsening? What does Trump’s tax bill mean for businesses?

Dyne at ‘attractive entry point’ following pullback, says Chardan

finance.yahoo.com/news/dyne-attractive-entry-point-following-134526819.html

In This Article:
Chardan notes Dyne Therapeutics (DYN) announced updates for its DYNE-101 program for myotonic dystrophy type 1, which included an update on regulatory alignment with the FDA regarding an accelerated approval pathway and updated data, out to 12-months, for the 6.8 mg/kg…

This story appeared on finance.yahoo.com, 2025-06-18 13:45:26.